Navigation Links
Organovo and OHSU Knight Cancer Institute Announce Collaboration in Cancer Research
Date:1/30/2013

SAN DIEGO, Jan. 30, 2013 /PRNewswire/ -- Organovo Holdings, Inc. (OTCQX: ONVO) ("Organovo"), a creator and manufacturer of functional, three-dimensional human tissues for medical research and therapeutic applications, and the Knight Cancer Institute at Oregon Health & Science University (OHSU), a national leader in translational oncology research, have formed a collaboration to develop more clinically predictive in vitro three dimensional cancer models which will ultimately advance discovery of novel cancer therapeutics. New biological models that more accurately replicate human cancer and malignant disease are desperately needed to enhance our understanding of how cancer develops and migrates and to deliver better oncology therapies for patients.

"The OHSU Knight Cancer Institute is consistently on the leading edge of cancer research, delivering true therapeutic breakthroughs like Gleevec," said Keith Murphy , chairman and chief executive officer at Organovo. "The knowledge and experience of the team at OHSU will be critical as we work together to create advanced models of cancer and metastasis that more reliably predict the safety and effectiveness of new therapeutics."

Today, animal models and cancer cell lines are used to identify and test potential drug candidates, but these tools have known limitations in their ability to predict clinical outcomes. More accurate and representative human disease models have the potential to improve drug discovery and development for a number of diseases, including cancer. By applying breakthrough bioprinting technology, Organovo develops three-dimensional, architecturally correct, human disease models to improve the understanding of drug toxicity and efficacy earlier in the drug development process, enabling safer, more effective therapies.

"A major challenge in oncology research today is that animal models cannot accurately represent human physiology, and cell lines do not provide information on how cells act in a three-dimensional, native architecture," said renowned cancer researcher Joe W. Gray , Ph.D., director of the OHSU Center for Spatial Systems Biomedicine (OCSSB), Gordon Moore chair of Biomedical Engineering in the OHSU School of Medicine and associate director for translational research for the OHSU Knight Cancer Institute. "Using Organovo's bioprinting technologies, we plan to create new models to understand cancer disease mechanisms and metastatic progression, which can be used to discover and test new targeted therapies." 

OHSU Knight Cancer Institute Director Brian Druker , M.D., added, "Better research models lead to a deeper understanding of disease mechanisms and more accurate information in the preclinical drug discovery and development process.

We believe new technologies, like bioprinting, are important for producing more relevant models of cancer and metastasis to ultimately support the discovery of new therapeutics."

About the OHSU Knight Cancer Institute
The Knight Cancer Institute at Oregon Health & Science University is a pioneer in personalized cancer medicine. The institute's director, Brian Druker , M.D., helped prove it was possible to shut down cells that enable cancer to grow without harming healthy ones. This breakthrough has helped make once-fatal forms of the disease manageable and ushered in a new generation of targeted cancer therapies. The OHSU Knight Cancer Institute is the only National Cancer Institute-designated Cancer Center between Sacramento and Seattle—an honor earned only by the nation's top cancer centers. It offers the latest treatments and technologies as well as hundreds of research studies and clinical trials. For more information, visit www.ohsu.edu/knight-cancer-institute

About Organovo Holdings, Inc.
Organovo designs and creates functional, three-dimensional human tissues for medical research and therapeutic applications. The company is collaborating with pharmaceutical and academic partners to develop human biological disease models in three dimensions. These 3D human tissues have the potential to accelerate the drug discovery process, enabling treatments to be developed faster and at lower cost. In addition to numerous scientific publications, their technology has been featured in The Wall Street Journal, Time Magazine, The Economist, and numerous others. Organovo is changing the shape of medical research and practice. Learn more at www.organovo.com.

Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including our current report on Form 8-K/A filed on May 11, 2012. We do not undertake to update these forward-looking statements made by us.


'/>"/>
SOURCE Organovo Holdings, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Market Boosted by Strong Tech Earnings: Bank of America Corp., MAP Pharmaceuticals Inc., Swingplane Ventures Inc., World Moto, Inc., Organovo Holdings, Inc.
2. Organovo Reports Q2 2012 Financial Results, Provides Business Update
3. Organovo, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
4. Organovo Announces Two Issued Patents, First Company Patent and Key Founder Patent
5. Organovo Holdings Appoints James T. Glover to Board of Directors
6. Anaptysbio Expands Leadership Team With Addition Of Dr. Andrew J. Mcknight
7. Global BioClinical Awarded Cancer Genome Atlas (TCGA) Contract
8. Dr. Alex Matter Awarded 2013 Szent-Gyorgyi Prize for Progress in Cancer Research
9. Ultrasound breast cancer imaging device created at the Karmanos Cancer Institute one step closer to FDA approval
10. Varian Equipment Selected to Equip New Cancer Center in Algeria and Enable More Advanced Radiotherapy Treatments for Patients
11. Elekta to Showcase Broad Portfolio of Cancer Management Solutions at 2013 Arab Health Congress and Exhibition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2017)... , Pa. and KALAMAZOO, Mich. , ... Allentown, Penn. , and OptiMed Specialty Pharmacy of ... business partnership to offer a strategic hub service that ... Healthcare,s highly sought-after personal spirometer, Spiro PD 2.0, and ... A spirometer is a medical device used to ...
(Date:9/12/2017)... , Sept. 12, 2017  ValGenesis Inc., the ... (VLMS), is pleased to announce the appointment of ... of its Board of Directors and Chairman of ... enables life science companies to manage their entire ... of paper in this process. Furthermore, ValGenesis VLMS ...
(Date:9/7/2017)... , Sept. 7, 2017  For nearly two decades, New Life Agency ... Assisted Reproduction Insurance industry. Today, New Life Agency announces a powerful three-way ... ... ... http://pharmacarecard.com/ (PRNewsfoto/PharmaCareCard) ...
Breaking Medicine Technology:
(Date:9/19/2017)... ... 19, 2017 , ... Peter Chandonait, Abt Associates Principal Scientist ... (PMI) Africa Indoor Residual Spraying (AIRS) Project , has been named the Grand ... Action Award, a USAID Catalyst Award, recognizes USAID staff and implementing partners who ...
(Date:9/19/2017)... ... September 19, 2017 , ... The Lymphoma Research ... lymphoma research and serving the lymphoma community through a comprehensive series of education ... part of its national Swirl: A Wine Tasting Event series on Thursday, October ...
(Date:9/19/2017)... (PRWEB) , ... September 19, 2017 , ... ... the addition of Canyon Ranch to its recently formed Corporate Roundtable, ... a sustainable healthcare system and a sustainable world. , Canyon Ranch is a ...
(Date:9/19/2017)... New York, NY (PRWEB) , ... September 19, ... ... Podiatry (ABMSP) has issued a rallying cry to Americans to watch for the ... late summer. From young athletes to senior citizens, everyone is at risk for ...
(Date:9/19/2017)... LEE, N.J. (PRWEB) , ... September 19, 2017 , ... ... the Subperiosteal Implant: Volume II ” (published by Xlibris on July of 2014). This ... and reviews conventional and new methodological approaches that benefit people who have lost all ...
Breaking Medicine News(10 mins):